An antibody-drug conjugate ... with another $1.525 billion in success-based milestones. It is playing catch-up with another B7-H3 ADC candidate from MSD and Daiichi Sankyo, ifinatamab deruxtecan ...

Pain significantly affects the quality of life and antibodies are being explored as a novel pain-relieving strategy.

The partnership unites RAD's products with AtomVie's capabilities in the manufacture and distribution of radiopharmaceuticals.

Tecentriq is a monoclonal antibody designed to bind with a protein ... blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq may enable the re-activation ...

The companies will collaborate to hold a global Phase I combination trial of YL201 and Amgen’s Imdelltra for small cell lung ...

The company highlighted in its statement the recent start of the IDeate-Lung02 of B7-H3-directed antibody-drug conjugate ... Therapeutics which is in phase 1/2.

ASX-listed Radiopharm Theranostics has joined forces with a renowned global radiopharmaceutical manufacturer to produce its cancer-fighting treatment that targets commonly over-expressed protein in ...

Only 3 (1%) were reported as treatment related interstitial ... LINker-payload (TMALIN®) conjugated with a highly specific B7-H3 antibody. Currently, YL201 is being investigated in four Phase ...

Top-line, phase 3 results for Bristol-Myers Squibb's humanized monoclonal antibody ... cell receptor B7, together with antigen presentation to the T-cell receptor (Fig. 1). Such 'co-stimulation ...

"Inebilizumab is a humanized monoclonal antibody that causes targeted and sustained depletion of CD19-positive B cells, ...

ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, today announced that it has entered into a ...

Co., Ltd. ("MediLink"), a clinical-stage biotech company, today announced a global clinical trial collaboration and supply ...